Journal article
Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
Abstract
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re-treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re-treatment was effective in patients with chronic plaque psoriasis.
OBJECTIVES: To describe the effects of tofacitinib withdrawal/re-treatment on health-related quality of life (HRQoL) and disease symptoms measured by patient-reported outcomes (PROs).
Authors
Griffiths CEM; Vender R; Sofen H; Kircik L; Tan H; Rottinghaus ST; Bachinsky M; Mallbris L; Mamolo C
Journal
Journal of the European Academy of Dermatology and Venereology, Vol. 31, No. 2, pp. 323–332
Publisher
Wiley
Publication Date
2 2017
DOI
10.1111/jdv.13808
ISSN
0926-9959